Determining the incidence of interstitial pneumonitis and chronic kidney disease following full intensity haemopoetic stem cell transplant conditioned using a forward-planned intensity modulated total body irradiation technique.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
05 2021
Historique:
received: 03 07 2020
revised: 01 02 2021
accepted: 15 02 2021
pubmed: 27 2 2021
medline: 21 5 2021
entrez: 26 2 2021
Statut: ppublish

Résumé

Total body irradiation (TBI) remains a key component of conditioning for allogeneic haemopoietic stem cell transplant (HSCT), with interstitial pneumonitis (IP) and chronic kidney disease (CKD) important late sequelae. We undertook a retrospective service evaluation of TBI patients treated with a forward-planned intensity modulated radiotherapy technique (FP IMRT). 74 adult patients were identified; all received step and shoot FP IMRT TBI, 14.4 Gy in 8 fractions over 4 days. Mean doses to the lungs and kidneys were 12-12.5 Gy. Toxicities were defined as per CTCAE v4.0: IP as multilobar infiltrates on CT with symptoms of dyspnoea, and renal dysfunction as an Estimated Glomerular Filtration rate (eGFR) < 60 ml/min/1.73 m Patients received treatment for the following diagnosis: ALL/LBL (n = 37); AML (n = 33), CML-BC (n = 2) and High grade NHL (n = 2). The rate of IP due to any cause was 30%; positive microbiological evidence in 73% (16 /22). Idiopathic IP was seen in 8%, with only 4% (n = 3) having IP Grade ≥ 3. Two (4%) of 52 long term survivors developed CKD, one with thrombotic microangiopathy. 4 year NRM was 16% (CI 11-32%); no treatment related deaths in matched sibling or umbilical cord blood HSCT. FP IMRT TBI, reducing dose to the lungs and kidneys, has lower rates of idiopathic IP and CKD compared to the literature. This technique is safe and effective conditioning for full intensity HSCT.

Identifiants

pubmed: 33636231
pii: S0167-8140(21)06083-7
doi: 10.1016/j.radonc.2021.02.020
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

97-103

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Emily Durie (E)

Department of Radiotherapy, The Royal Marsden Hospital, Sutton, United Kingdom.

Emma Nicholson (E)

Haemato-Oncology Unit, The Royal Marsden Hospital, Sutton, United Kingdom.

Chloe Anthias (C)

Haemato-Oncology Unit, The Royal Marsden Hospital, Sutton, United Kingdom.

Emma M Dunne (EM)

Department of Radiotherapy, The Royal Marsden Hospital, Sutton, United Kingdom.

Mike Potter (M)

Haemato-Oncology Unit, The Royal Marsden Hospital, Sutton, United Kingdom.

Mark Ethell (M)

Haemato-Oncology Unit, The Royal Marsden Hospital, Sutton, United Kingdom.

Christina Messiou (C)

Radiology Department, The Royal Marsden Hospital, Sutton, United Kingdom.

Joy Brennan (J)

Haemato-Oncology Unit, The Royal Marsden Hospital, Sutton, United Kingdom.

Sally Eagle (S)

Department of Radiotherapy, The Royal Marsden Hospital, Sutton, United Kingdom.

James Talbot (J)

Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.

Gregory Smyth (G)

Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.

Westley Ingram (W)

Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.

Frank Saran (F)

Department of Radiotherapy, Auckland City Hospital, New Zealand.

Henry C Mandeville (HC)

Department of Radiotherapy, The Royal Marsden Hospital, Sutton, United Kingdom; The Institute of Cancer Research, Sutton, United Kingdom. Electronic address: henry.mandeville@rmh.nhs.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH